Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex's Kidney Disorder Drug VX-147 Reduces Proteinuria in Phase 2 Study

12/01/2021 | 09:27am EST


ę MT Newswires 2021
All news about VERTEX PHARMACEUTICALS
01/21NORTH AMERICAN MORNING BRIEFING : Dow Wobbles, -3-
DJ
01/20WALL STREET STOCK EXCHANGE : Nasdaq aims for rebound after entering correction territory
01/20ANALYST RECOMMENDATIONS : Activision Blizzard, AMD, Bumble, Etsy, Ford...
01/20BMO Capital Lifts Vertex Pharmaceuticals to Outperform From Market Perform, Price Targe..
MT
01/19SiteOne Therapeutics Announces Collaboration and License Agreement with Vertex Pharmace..
CI
01/18Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
BU
01/12Vertex Pharmaceuticals - European Commission Approves KAFTRIO (ivacaftor/tezacaftor/ele..
AQ
01/11Vertex's Cystic Fibrosis Combo Gets Extended EU Nod For Treating Children
MT
01/11Vertex Secures European Commission's Approval for Kaftrio With Ivacaftor as Treatment f..
MT
01/11European Commission Approves KAFTRIO« (ivacaftor/tezacaftor/elexacaftor) in Combination..
BU
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 7 502 M - -
Net income 2021 2 295 M - -
Net cash 2021 8 192 M - -
P/E ratio 2021 25,8x
Yield 2021 -
Capitalization 57 743 M 57 743 M -
EV / Sales 2021 6,61x
EV / Sales 2022 5,57x
Nbr of Employees 3 400
Free-Float -
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 227,11 $
Average target price 268,39 $
Spread / Average Target 18,2%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS3.42%57 743
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
WUXI APPTEC CO., LTD.-7.49%50 700
BIONTECH SE-39.30%37 796
BEIGENE, LTD.-13.83%23 988